Radiation and Lutetium PSMA for locally advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that was confirmed by biopsy.
- A PSMA PET scan within the last 4 months shows the main tumor has high PSMA activity (SUVmax of 10 or more).
- The cancer has either spread to nearby lymph nodes or has certain high-risk features (large tumor, Gleason grade group 4 or more, or PSA 40 or higher).
- You have not had any prior treatment for your prostate cancer (like surgery, radiation, or hormone therapy).
- You are generally healthy enough for treatment (good kidney, blood, and liver function) and do not have other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Hear when a new Locally Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.